Intragastric injection botulinum toxin A for obesity management with or without liraglutide.

Eur Rev Med Pharmacol Sci

Department of Perfusion Techniques, School of Medicine, Nişantaşı University, Istanbul, Turkey.

Published: April 2023

Objective: Obesity is a global public health problem with rapidly increasing prevalence in many countries, including Turkey, and different treatment modalities have been used. This study aimed to compare the effect of intragastric botulinum toxin A (BTA) injection and BTA injection combined with low-dose liraglutide in patients with obesity.

Patients And Methods: Records of 701 patients (female/male, 660:41; mean age, 45.6 ± 6.2 years) who received an intragastric injection of BTA for weight loss between November 2019 and May 2020 were reviewed retrospectively. The patients were divided into the BTA group, which included patients who received BTA injection alone, and BTA + liraglutide, which included those who used liraglutide after BTA injection. The demographic characteristics and comorbid diseases of the patients and follow-up results 6 months after the procedure were evaluated.

Results: In the comparison of the 3-month and 6-month weights of the patients, weight measurements were significantly lower in the BTA + liraglutide group than in the BTA group (p < 0.001 and p  < 0.001, respectively). Adverse effects were observed in 212 (30.2%) of the study participants, of which 25% were observed in the BTA group and 31.8% in the BTA + liraglutide group, with no significant difference.

Conclusions: The intragastric injection of BTA combined with liraglutide is a safe method that provides more effective weight loss than BTA alone, which is minimally invasive without any serious adverse effects.

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_202304_32128DOI Listing

Publication Analysis

Top Keywords

bta injection
16
injection bta
16
bta
13
intragastric injection
12
bta group
12
bta liraglutide
12
botulinum toxin
8
weight loss
8
liraglutide group
8
adverse effects
8

Similar Publications

Introduction: To date, no investigations have been published regarding the concentration, dose, and technique for a mucosal spray application of botulinum toxin A (BTA) to alleviate hypersecretory symptoms of rhinitis in humans. It is a promising option for reducing common symptoms of seasonal allergic rhinitis (AR) and idiopathic non-AR. It is safer and less painful than intranasal injections, with high reported satisfaction in reducing clinical symptoms.

View Article and Find Full Text PDF

Objective: Spasticity developing in the upper extremity in stroke patients causes disability by limiting movement and causing pain. This study investigates the effects of botulinum toxin injections on pain, functionality, spasticity, and range of motion in hemiplegic patients with post-stroke spasticity.

Materials And Methods: The study involved a double-blind, prospective, randomized controlled trial with thirty-one stroke patients aged 35-80 who developed upper extremity spasticity.

View Article and Find Full Text PDF

Intragastric botulinum toxin injection for weight loss: current trends, shortcomings and future perspective.

Clin Endosc

November 2024

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

The administration of botulinum toxin A (BTA) into the gastric wall has emerged as a novel endoscopic bariatric procedure. Although over 20 years have elapsed since the initial human trial of intragastric BTA injection, considerable debate remains surrounding the safety, efficacy, and procedural instructions of this approach. The current literature exhibits discrepancies in the methodologies employed across studies, including differences in the dosage of BTA administered, injection site, number and depth of injections, post-procedural dietary modifications, and follow-up duration.

View Article and Find Full Text PDF

Objective: The purpose of this meta-analysis was to evaluate the therapeutic efficacy and safety of botulinum toxin A (BTA) injections for treatment of plantar fasciitis (PF).

Methods: This review adhered to the PRISMA guidelines, conducting a comprehensive search of the PubMed, Web of Science, EMBASE, and Cochrane Library databases for eligible studies from their inception to December 30 2023. The inclusion criteria were limited to randomized controlled trials (RCTs) comparing BTA injections with control interventions in terms of pain reduction, functional improvement, or the occurrence of adverse events in treating patients with PF were extracted for meta-analysis.

View Article and Find Full Text PDF

Open ventral hernia repair is one of the most commonly performed surgeries by general surgeons worldwide. In the case of complex incisional hernias, there are adjunct techniques that can help abdominal wall reconstruction surgery, such as type A botulinum toxin (BTA), whose injection results in muscle relaxation and growth of muscle fiber length, allowing fascial closure without the need for advanced techniques. We report a case of a male patient who underwent ultrasound-guided BTA injection in the abdominal wall and, five days later, was admitted to our emergency department with dysarthria, muscular weakness, dyspnea on small exertion, and constipation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!